Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

Morie Gertz, Martha Lacy, John A. Lust, Philip R. Greipp, Thomas Elmer Witzig, Robert A. Kyle

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalMedical Oncology
Volume16
Issue number2
StatePublished - Jul 1999

Fingerprint

Dexamethasone
Melphalan
Prednisone
Survival
Immunoglobulin Light Chains
Amyloidosis
Multiple Myeloma
Primary amyloidosis
Therapeutics
Prospective Studies
Drug Therapy

Keywords

  • Amyloidosis
  • Corticosteroid therapy
  • Dexamethasone therapy
  • Nephrotic syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. / Gertz, Morie; Lacy, Martha; Lust, John A.; Greipp, Philip R.; Witzig, Thomas Elmer; Kyle, Robert A.

In: Medical Oncology, Vol. 16, No. 2, 07.1999, p. 104-109.

Research output: Contribution to journalArticle

@article{3b4a66dcfb394bc5943735af2a591c9c,
title = "Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis",
abstract = "Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.",
keywords = "Amyloidosis, Corticosteroid therapy, Dexamethasone therapy, Nephrotic syndrome",
author = "Morie Gertz and Martha Lacy and Lust, {John A.} and Greipp, {Philip R.} and Witzig, {Thomas Elmer} and Kyle, {Robert A.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "16",
pages = "104--109",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

AU - Gertz, Morie

AU - Lacy, Martha

AU - Lust, John A.

AU - Greipp, Philip R.

AU - Witzig, Thomas Elmer

AU - Kyle, Robert A.

PY - 1999/7

Y1 - 1999/7

N2 - Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.

AB - Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.

KW - Amyloidosis

KW - Corticosteroid therapy

KW - Dexamethasone therapy

KW - Nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0032796593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032796593&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 104

EP - 109

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 2

ER -